TNF-α

TNF-α agonistic 1, a TNF-α agonistic compound, could induce cells to secrete TNF- α.

TNF-α-IN-1 is a TNF-α inhibitor.

TNF-α (31-45), human, is a peptide of tumor necrosis factor-α.

TNF-α-IN-25 exhibits weak to moderate inhibition of the hERG-encoded potassium ion channel, with a hERG IC50 value of 9.2 μM.

TNF-α-IN-26 (Compound 18) is a TNF-α inhibitor, exhibiting an IC50 of 0.10 μM for the CSBP ligand. It suppresses LPS-stimulated TNF production in mouse models and is applicable in research on inflammatory diseases.

TNF-α-IN-6 is an orally efficacious, allosteric inhibitor of TNFα (K_D = 6.8 nM).

TNF-α (31-45), human (TFA), is a peptide of tumor necrosis factor-α (TNF alpha), an inflammatory cytokine that induces necrosis or apoptosis.

TNF-α-IN-11 (Compound 10) is a TNF-α inhibitor with a dissociation constant (K D) of 12.06 μM. It impedes TNF-α-induced caspase activation and the NF-κB signaling pathway by binding to TNF-α, suppressing the phosphorylation of IκBα and the nuclear migration of NF-κB p65. This compound is utilized in the study of TNF-α-mediated autoimmune diseases [1].

TNF-α-IN-10 (compound 8a) is an inhibitor of IL-6 and TNF-α, exhibiting anti-inflammatory activity [1].

TNF-α-IN-18 (Compound 61) is a small molecule inhibitor of tumor necrosis factor-alpha (TNF-α) that operates with a IC50 of 1.8µM. TNF-α-IN-18 effectively blocks the nuclear translocation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), thereby suppressing the downstream TNF signaling pathway; TNF-α-IN-18 exhibits minimal cytotoxicity in mouse fibroblast LM cells with a CC50 greater than 50 µM. TNF-α-IN-18has been shown to alleviate sepsis induced by TNF or lipopolysaccharide in mouse models, and provides significant protection against the development and progression of rheumatoid arthritis in murine models.

TNF-α-IN-22 (Compound 30) is a TNFα inhibitor that induces apoptosis by inhibiting TNFα-induced IkBα downregulation and blocking the cell cycle. It is applicable for research in triple-negative breast cancer.

TNF-α-IN-24 (Example 15) is a TNF-α inhibitor with an IC50 value of 4.1 nM. It is applicable in research on inflammatory and autoimmune diseases such as rheumatoid arthritis and Crohn's disease.

TNF-α-IN-8 (compound I-42) is an isoindole-imide inhibitor of tumor necrosis factor-alpha (TNF-α), used in research on cancer, heart disease, osteoporosis, and autoimmune disorders. It also acts as a click chemistry reagent, with an Azide group suitable for CuAAc or SPAAC reactions with Alkyne, DBCO, or BCN groups.

TNF-α (10-36), human, is a potent pro-inflammatory cytokine involved in the acute phase stress response.

Human TNF alpha (46-65) peptide.

TNF-α-IN-2 is an effective and orally active TNFα inhibitor that distorts the TNFα trimer upon binding, causing abnormal signal transduction when it binds to TNFR1, and can be used to study rheumatoid arthritis.

TNF-α (31-45), human acetate is a peptide of tumor necrosis factor-α.

TNF-α/IL-1β-IN-1 (compound 11a) is an anti-inflammatory agent that effectively reduces the expression of TNF-α and IL-1β, inhibits oxidative stress and myocardial cell apoptosis, and demonstrates significant activity against septic myocardial injury. Additionally, it improves myocardial blood flow in vivo.

TNF-α antagonist is an exocyclic peptide that mimics the critical TNF-α recognition loop on TNF receptor I complex and, thus, prevents ligand interaction with the receptor. By blocking the TNF receptor ligand contact site, this peptide interferes with both activating receptor activator of NF-κB (RANK) and TNF-α's recruitment and activation of osteoclasts. TNF-α antagonist has been used to block bone resorption in the study of systemic bone loss in rheumatoid arthritis and inflammatory bone destruction.

TNF-α-IN-9 is an NDM-1 inhibitor-3 analog and is a TNF-α inhibitor.TNF-α-IN-9 shows low inhibitory activity.

TNF-α-IN-12, a TNF-α inhibitor with an IC50 of 0.1 μM, can reduce TNF-α blood levels [1].

TNF-α-IN-13, a potent inhibitor of TNFα, exhibits an IC 50 of less than 0.6 μM and possesses antiinflammatory properties (WO2001072735A2; example 6) [1].

TNF-α-IN-14, a potent TNFα inhibitor, exhibits a selective inhibition profile with an IC50 of 1.1 µM and demonstrates antiinflammatory properties (WO2001072735A2; compound 12) [1].

TNF-α-IN-15, a TNF-α inhibitor, effectively reduces TNF-α blood levels [1].